Dr. Moseley arrived at the Duke Proteomics Core Facility in 2007 looking for answers, answers to the most challenging questions involving protein biomarkers.
“What can we do with a sample of human tissue or body fluid by looking at the proteome?” he wondered. “Can we determine whether a person is sick or not? Can we predetermine how that person will respond to a certain drug? Can we prevent an adverse drug reaction?”
To answer those questions, he would have to create an entirely new facility from the ground up. And that’s exactly what he did, from designing the lab to specifying, acquiring, and implementing all instrument hardware and software required. His design provided the facility with the capability to support a diverse range of proteomic research projects, from studies in Basic Sciences Departments through support of clinical trials for Clinical Sciences Departments. The clinical support has included biomarker discovery studies in the areas of oncology, immunology, and infectious disease. In 2009 the lab completed 8 clinical proteomics projects, as well as 6 pilot-scale clinical proteomics projects.
Prior to his appointment at Duke University, Dr Moseley had managed mass spectrometry laboratories at GlaxoSmithKline (GSK) for sixteen years; for six years of those years he led a transnational laboratory (US/UK) dedicated to proteomic biomarker discovery. Key among his accomplishments was leading a collaboration with Waters in the development and implementation of a coupled nanoscale liquid chromatography – tandem mass spectrometry (LC/MS/MS) based proteomic platform using gel-free, label-free methodologies.
In his three short years at Duke, Dr. Moseley has not only created a new facility, he has generated the type of high quality, reproducible data that will help answer some of biology’s most complex questions.
“Waters liquid chromatography and mass spectrometry make an important contribution to our research,” says Dr. Moseley. “By providing data that is reproducible and quantifiable, it allows scientists to ask more meaningful questions about fundamental biology and protein interactions which, in turn, should lead to meaningful answers.”
Dr. Moseley shares his thoughts on why biomedical science has reached a tipping point and what must come next for real progress to resume.
Dr. Moseley tells Biotechniques Magazine how and why he uses nanoscale LC-MS-MS.